Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cireng.2021.05.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient-reported outcomes in patients with peristomal pyoderma gangrenosum: A single-center prospective study.
JAAD Case Rep
January 2025
Department of Dermatology, Oregon Health and Science University, Portland, Oregon.
Rapid and Sustained Resolution of Peristomal Pyoderma Gangrenosum With Aerosol Steroid Treatment.
J Wound Ostomy Continence Nurs
January 2025
Kyriaki Stefania Mitsaki, MBBCh, BSc (Hons), MSc, MRCP, Department of Dermatology, Northwick Park Hospital, London North West University Hospital NHS Trust, London, UK.
Background: Peristomal pyoderma gangrenosum (PPG) is a non-infectious neutrophilic dermatosis most commonly seen in the context of ostomies in inflammatory bowel disease. The lack of established treatment guidelines and high-quality evidence in the form of randomized controlled trials present a major challenge in PPG management, owing to the rarity of the condition. Treatment can be further complicated by difficulties in maintaining the stoma pouch seal with conventional topical corticosteroids.
View Article and Find Full Text PDFFeatures, Treatments, and Therapeutic Outcomes of Peristomal versus Non-Peristomal Pyoderma Gangrenosum in 45 Patients with Inflammatory Bowel Disease: A Single-Institution Study, 2002 through 2021.
Skinmed
January 2025
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA.
Pyoderma gangrenosum (PG) is the second most common skin manifestation reported in patients with inflammatory bowel disease (IBD). We performed a single-institution, retrospective study to summarize the clinical features and examine effective treatment regimens and outcomes of PG in IBD patients. We identified 45 patients who presented to our institute between January 1, 2002 and December 31, 2021 with the following criteria: (1) diagnosed with an active PG (ICD9: 686.
View Article and Find Full Text PDFTopical corticosteroid powder for peristomal pyoderma gangrenosum: a systematic review.
Wounds
October 2024
Department of Dermatology, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: Peristomal pyoderma gangrenosum (PPG) is a critical complication after surgical ileostomy or colostomy placement. While topical treatments are often effective, most of the available vehicles reduce ostomy pouch adhesion. There are no commercially available corticosteroid powders for topical application; however, using powder from crushed corticosteroid tablets or capsules may circumvent this issue.
View Article and Find Full Text PDFPeristomal skin lesions - identifying patients at risk.
Z Gastroenterol
November 2024
Department of Dermatology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Uniklinikum Erlangen, Erlangen, Germany.
Article Synopsis
- Diagnosis and treatment of peristomal skin lesions are complex due to a lack of validated diagnostic tools.
- In a study of 565 ostomy patients, 40.2% had skin lesions, with moisture-related damage being the most frequent, followed by ulcerations and eczema.
- A significant portion of patients with inflammatory bowel disease experienced higher rates of peristomal ulcerations and pyoderma gangrenosum, indicating the need for better assessment and classification of these lesions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!